Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A single dose of typhoid conjugate vaccine (TCV) offers safe, effective protection against typhoid two years after vaccination in all children, and sustained protection for older children at three to five years post immunisation, according to a report by researchers at the Oxford Vaccine Group and the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b). But it also shows a decline in protection at the later timepoints among children vaccinated at younger ages.

Female doctor or nurse vaccinating a kid. © icddr,b

The TyVOID study, published in the Lancet, measured the effectiveness of a single dose TCV in Bangladeshi children over a five-year period and confirmed the high vaccine protection (80-96%) within two years of vaccination in all children.

Three to five years after vaccination, the study found a three-fold increase in typhoid incidence in children who received TCV in 2018/2019 and those who received it in 2021, suggesting a decline in vaccine effectiveness, most pronounced in the very young. The data suggested children vaccinated at two years or older were still well protected (59-85%) at 3-5 years post vaccination however, a more significant decline in protection was seen in children vaccinated at under two years of age, suggesting that a booster dose for these children might be needed for sustained protection.

Xinxue Liu, Associate Professor of Medical Statistics and Epidemiology at the Oxford Vaccine Group, and one of the senior authors of the study, said: 'Typhoid is a serious and life-threatening enteric fever that remains a substantial public health issue for children and adolescents in low- and middle-income countries. TCV offers the best chance to reduce the burden of typhoid, helping to reduce transmission and limiting further evolution of drug-resistant strains. This study provides additional information for policy makers on longer-term TCV protection and the importance of continued investigation and updated guidance.'

Dr Firdausi Qadri, Senior Scientist at the Infectious Diseases Division at the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), and first author on the study, said: 'This TyVOID study followed the original TyVAC cluster randomised controlled trial population for another two and a half years after unmasking in 2021. The results indicate a decay in antibody concentrations in different age groups and suggest that a booster dose around school entry age for children vaccinated while younger than 2 years could be considered, to sustain the protection from TCV through the school years when children are at greatest risk of typhoid.'

 

Read the full story on the University of Oxford website.

 

Similar stories

First clinical study in GSK-Oxford Experimental Medicine Collaboration starts as first patient dosed in ulcerative colitis experimental trial

The first patient in the PEGASUS clinical study, part of the GSK-University of Oxford Experimental Medicine Collaboration, received the first dose last week, on 8 October 2026.

Wearable chest patch could support hospital-level care at home, study finds

Researchers in Oxford have shown that wearable chest patches can be used to effectively monitor vital signs in many acutely unwell patients receiving hospital-level care in their own homes.

Brain immune cells protect neurons in Parkinson’s disease by “nibbling” harmful material

New research, published in Science Translational Medicine, reveals how a specialised population of the brain’s immune cells can remove harmful protein clumps from nerve cells (neurons), pointing to potential new treatments for Parkinson’s disease.

Phase I clinical study of ChAdOx1 BDBV vaccine launches in Uganda

The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM Uganda Research Unit) has launched a Phase I clinical study evaluating the safety and immunogenicity of a candidate vaccine against Bundibugyo virus disease (BVD), a severe form of Ebola virus disease caused by Bundibugyo virus (BDBV), in partnership with the University of Oxford.

The Nuffield Department of Women's & Reproductive Health's Clinical Research Group recruits its 2,000th participant to the Generation Study

Oxford’s Clinical Research Group (CRG) has reached an important milestone after recruiting its 2,000th participant to the nationwide Generation Study.

Dementias Platform UK (DPUK) blood biomarker project takes next step towards NHS dementia diagnosis

A project involving researchers from the Universities of Oxford and Cambridge, Imperial College London and Dementias Platform UK (DPUK) has been selected for a major UK initiative aimed at improving dementia diagnosis and helping more people access the support and treatment they need sooner.